LipoSwift LNP - In Vivo Lung-Targeting Kit

The in vivo series is developed using proprietary lipid nanoparticle (LNP) technology, systematically designed to meet diverse in vivo nucleic acid application needs, achieving high delivery efficiency, precise targeting, and excellent biocompatibility. One of the key features of this series of kits is its ease of use while maintaining a high transfection efficiency. It is designed for a simple, single-step encapsulation process that does not require any specific LNP encapsulation equipment.

The LipoSwift LNP – In Vivo Lung-Targeting Kit is a state-of-the-art LNP formulation system designed specifically for efficient and selective delivery of nucleic acids to lung tissue in vivo. The lungs are a highly dynamic and crucial organ, serving as the gateway for gas exchange and a frequent site for diseases ranging from infectious diseases like influenza and COVID-19 to chronic conditions such as cystic fibrosis and asthma, and serious malignancies like lung cancer. The ability to precisely and efficiently deliver nucleic acid payloads—be it mRNA for vaccination, gene editing tools, or siRNA for gene silencing—to the cells of the lung is a critical bottleneck in the development of effective treatments. This kit overcomes this challenge through a meticulously controlled formulation. Our patented lipid composition and assembly process are finely tuned to achieve highly efficient and selective accumulation of the LNP-nucleic acid complex in the pulmonary system. Whether your goal is pulmonary gene therapy, mechanistic studies, or preclinical proof-of-concept research, this kit provides the precision, efficiency, and reproducibility required to translate your ideas into impactful scientific results.

• Unprecedented Lung Targeting Efficacy: The most significant advantage of our kit is its remarkable lung-targeting specificity. Unlike non-targeted LNPs which tend to accumulate non-specifically in the liver and spleen after intravenous injection, our finely tuned formulation actively directs the LNP payload to the lungs.
• Broad Payload Compatibility: The kit supports encapsulation of various nucleic acid modalities, including mRNA, siRNA, saRNA, circRNA, and shRNA, enabling a wide range of applications in basic research and therapeutic development.
• Single-Step Encapsulation Without Special Equipment: The kit enables encapsulation in one simple step using standard laboratory pipettes, drastically reducing the time and cost associated with LNP preparation.
• High Transfection Efficiency: Performance benchmarks show that LNPs prepared with this kit achieve transfection efficiencies comparable to LNPs made with professional encapsulation systems, ensuring that researchers do not compromise on data quality when opting for simplicity.
• Excellent Biocompatibility: The proprietary lipid composition of LipoSwift nanoparticles is optimized for low immunogenicity and high stability in physiological environments, ensuring minimal adverse effects and better tolerability in vivo.

The efficacy and specificity of the LipoSwift LNP - In Vivo Lung-Targeting Kit have been rigorously validated through extensive preclinical studies. Here, we present compelling evidence demonstrating the kit's superior performance in a murine model.

LipoSwift LNP - In Vivo Lung -Targeting Kit User Manual